We still dont have long-term human safety data for BPC-157, and thats something we must acknowledge. For him, however, the greatest concern isnt necessarily the peptide itself
The EMA classifies it as safe, and adverse effects reported in clinical trials are generally mild and transient
"Cagrilintide clinical development program: Phase 3 trial results." Corporate Research Publications
A randomized, controlled trial involving nearly 2,000 adults with overweight or obesity but without diabetes was conducted
(5.2) Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin: Concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia
It's mostly in foods with lots of protein